Severe Bradycardia, Renal Failure, Atrioventricular Nodal Blockade, Shock, and Hyperkalemia (BRASH) Syndrome Successfully Managed With Transvenous Pacing and Continuous Renal Replacement Therapy Authors: Disha C Shetty, Sankalp Acharya, Hans Jesper F Del Mundo, Raghav Gera, Hardikkumar Bhanderi Published: 2026 ABSTRACT BRASH (Bradycardia, Renal failure, Atrioventricular nodal blockade, Shock, and Hyperkalemia) syndrome is a life-threatening clinical syndrome characterized by a vicious cycle in which hyperkalemia and AV nodal blocking medications synergistically produce profound bradycardia and hemodynamic instability.A 71-year-old male with stage IIIB chronic kidney disease (CKD), heart failure with improved ejection fraction, and coronary artery disease status post coronary artery bypass grafting, on carvedilol, losartan, and torsemide, was brought to the emergency room from a rehabilitation facility for a syncopal event and unresponsiveness. He had been recently hospitalized for multifocal pneumonia and respiratory syncytial virus infection, with suspected volume depletion and ongoing AV nodal blockade contributing to the development of BRASH syndrome. He was in respiratory distress, profound shock, and bradycardia with a heart rate of 30 BPM. Labs revealed severe acute kidney injury (creatinine 6.2 mg/dL), hyperkalemia (6.9 mmol/L), and metabolic acidosis (pH 7.19). Chest radiograph demonstrated pulmonary edema. His condition rapidly progressed to airway compromise requiring intubation, cardiogenic shock requiring vasopressors, and refractory bradycardia necessitating transvenous pacing after failure of atropine, dopamine, and transcutaneous pacing. He was admitted to the intensive care unit and promptly initiated on continuous renal replacement therapy (CRRT), resulting in correction of electrolyte and acid-base abnormalities with subsequent resolution of severe bradycardia, allowing discontinuation of transvenous pacing. Infectious workup remained negative, and echocardiography demonstrated preserved left ventricular systolic function. Following stabilization, he was successfully extubated and weaned off CRRT. His subsequent hospital course was complicated by recurrent oliguric renal failure requiring initiation of intermittent hemodialysis. Upon discharge, he remained hemodynamically stable with improved mental status and was planned for long-term hemodialysis and inpatient rehabilitation.The synergistic interaction of hyperkalemia and AV nodal blockade is the central pathophysiologic mechanism underlying BRASH syndrome. Common triggers include hypovolemia and medications that promote AV nodal blockade or hyperkalemia in vulnerable patients with advanced age, CKD, and heart failure. The resulting profound bradycardia further reduces cardiac output, worsening renal perfusion and perpetuating hemodynamic instability. Prognosis depends largely on early recognition and prompt intervention. This case highlights a severe presentation of BRASH syndrome in which timely initiation of CRRT corrected the underlying metabolic derangements, and transvenous pacing provided temporary hemodynamic support, ultimately leading to clinical recovery. Introduction BRASH (Bradycardia, Renal failure, Atrioventricular nodal blockade, Shock, and Hyperkalemia) syndrome is an increasingly recognized clinical syndrome characterized by a vicious cycle in which hyperkalemia and AV nodal blocking medications synergistically produce profound bradycardia and hemodynamic instability [1]. Most commonly occurring in elderly patients with chronic kidney disease (CKD) and cardiovascular comorbidities, BRASH syndrome is frequently precipitated by acute kidney injury (AKI), hypovolemia, or medication-related renal dysfunction [1]. Unlike isolated hyperkalemia or AV nodal blocker overdose, BRASH syndrome involves the simultaneous interaction of multiple pathophysiologic processes, often resulting in rapidly progressive shock and multiorgan failure if not promptly recognized and treated [1]. We present a severe case of BRASH syndrome complicated by circulatory shock, respiratory failure, transvenous pacing requirement, and continuous renal replacement therapy (CRRT) in a patient with significant underlying cardiac and renal disease. Case presentation A 71-year-old male with stage IIIB CKD, heart failure with improved ejection fraction, and coronary artery disease status post coronary artery bypass grafting (CABG), on home medications including carvedilol, losartan, and torsemide, was brought to the emergency room from a rehabilitation facility for a syncopal event and unresponsiveness. Notably, he had been recently hospitalized for acute hypoxic respiratory failure secondary to multifocal pneumonia and respiratory syncytial virus (RSV) infection, raising concern for ongoing volume depletion and renal hypoperfusion in the setting of continued AV nodal blockade and renin-angiotensin system inhibition as potential precipitating factors for BRASH syndrome. On admission, he was in respiratory distress, profound shock with a blood pressure of 71/38 mmHg, and bradycardia with a heart rate of 30 BPM. Labs revealed creatinine of 6.2 mg/dl (reference range: 0.50 - 1.20 mg/dL), hyperkalemia of 6.9 mmol/L (reference range: 3.5 - 5.0 mmol/L), and acute metabolic acidosis with a pH of 7.19 (reference range: 7.35 - 7.45). Electrocardiogram revealed a junctional rhythm with a ventricular rate of 46, left anterior fascicular block, and occasional premature ventricular complexes as seen in Figure 1. Classic hyperkalemia-associated electrocardiographic changes such as peaked T waves and QRS widening were notably absent. Chest radiograph showed pulmonary edema. His clinical course rapidly progressed to respiratory failure requiring intubation, cardiogenic shock requiring pressors, and hemodynamically unstable bradycardia refractory to atropine, dopamine, and transcutaneous pacing, necessitating transvenous pacing. Electrocardiogram showing junctional rhythm with a ventricular rate of 46 and left anterior fascicular block. He was admitted to the intensive care unit and was promptly initiated on CRRT, resulting in resolution of electrolyte abnormalities and acid-base derangements. Bradycardia also subsequently improved with a native heart rate in the 80s. Repeat electrocardiogram showed that a normal sinus rhythm had replaced the junctional rhythm, as seen in Figure 2. The temporary transvenous pacemaker remained in place for eight hours. It was discontinued after the patient's heart rate and rhythm stabilized, hyperkalemia and renal function improved, AV nodal blocking medications were held, and the patient maintained an adequate intrinsic rhythm without pacing requirements or recurrent hemodynamic instability. Despite an initial concern for sepsis, extensive infectious workup remained negative, and empiric antibiotics were discontinued. Echocardiogram showed normal left ventricular systolic function. Electrocardiogram showing normal sinus rhythm and improved rate of 91 following initiation of continuous renal replacement therapy and discontinuation of transvenous pacing. Following stabilization, he was successfully extubated with improvement in mental status and renal function, allowing discontinuation of CRRT. However, after transfer to the medical floor, he developed recurrent renal failure with oliguria, necessitating initiation of intermittent hemodialysis (IHD). At the time of discharge, the patient was hemodynamically stable, cognitively improved, tolerating oral intake, and planned for long-term hemodialysis and inpatient rehabilitation. Discussion This case illustrates a severe presentation of BRASH syndrome in a patient with pre-existing CKD and heart failure, resulting in cascading multiorgan failure requiring intensive care unit admission, transvenous pacing, vasopressor support, and CRRT. BRASH syndrome is a recently recognized clinical entity describing the synergistic interaction between hyperkalemia and AV nodal blocking medications that produces hemodynamically significant bradycardia and circulatory shock [1,2]. The syndrome is initiated when a precipitating event, most commonly hypovolemia, infection, or medications promoting hyperkalemia or renal injury, triggers AKI in a patient taking AV nodal blocking agents such as beta blockers, calcium channel blockers, or amiodarone [1]. The resulting decline in renal function leads to accumulation of both potassium and AV nodal-blocking drugs, as many of these agents are renally cleared or have enhanced effects in the setting of electrolyte derangements [1,3]. Hyperkalemia and AV nodal blockade then act synergistically to produce profound bradycardia that is disproportionate to the degree of either derangement alone [1,3]. The ensuing bradycardia reduces cardiac output, further compromising renal perfusion and perpetuating a vicious cycle of worsening renal failure, progressive hyperkalemia, and deepening hemodynamic instability [1,3]. Beta-blocker accumulation may vary by agent. While some agents are renally cleared and can accumulate in AKI, others, such as carvedilol, are primarily hepatically metabolized and are less affected by renal dysfunction [1,3]. Nevertheless, even in the absence of substantial drug accumulation, AV nodal blockade can act synergistically with hyperkalemia to precipitate the profound bradycardia characteristic of BRASH syndrome. This patient’s presentation illustrates the classic pathophysiologic cascade of BRASH syndrome. His underlying CKD, heart failure with improved ejection fraction, and coronary artery disease status post-CABG, along with treatment with carvedilol and losartan, predisposed him to impaired potassium and medication clearance. An acute trigger, such as his recent illness with multifocal pneumonia and RSV infection, was associated with AKI on CKD, resulting in hyperkalemia, metabolic acidosis, and accumulation of AV nodal blockade, culminating in hemodynamically unstable bradycardia requiring transvenous pacing and vasopressor support. A critical aspect of this case is the importance of recognizing BRASH syndrome as a distinct entity rather than attributing the clinical picture to isolated hyperkalemia or AV nodal blocker overdose, as the management differs significantly [1,2]. In isolated hyperkalemia, the potassium level is typically severely elevated (often >7.0 mEq/L) and produces characteristic electrocardiographic changes, including peaked T waves, widened QRS complexes, and sine wave patterns [1]. In contrast, BRASH syndrome can produce hemodynamically significant bradycardia at only moderately elevated potassium levels (e.g., 5.5-6.5 mEq/L) due to the synergistic effect with AV nodal blockade [1,3]. Similarly, BRASH syndrome should be distinguished from AV nodal blocker overdose, in which a supratherapeutic dose of the medication is the primary driver; in BRASH syndrome, patients are typically on therapeutic doses of their medications, and the toxicity arises from impaired clearance and synergy with hyperkalemia rather than intentional or accidental overdose [1]. This distinction has important therapeutic implications. Standard bradycardia management emphasizes atropine and cardiac pacing, but these measures alone are often insufficient in BRASH syndrome because they fail to correct the underlying metabolic derangements perpetuating the cycle [1,2]. A systematic scoping review by Shah et al. found that atropine and glucagon were ineffective in reversing symptoms in the majority of BRASH syndrome cases, and 59.5% of 71 patients required inotropes or chronotropes [2]. Treatment of BRASH syndrome requires a multimodal approach targeting all components simultaneously: fluid resuscitation to restore renal perfusion, aggressive hyperkalemia management (intravenous calcium, insulin/glucose, beta agonists), discontinuation of the offending AV nodal blocker, and management of bradycardia-induced shock with vasopressors, preferably epinephrine, which provides both chronotropic and vasopressor support [1]. In refractory cases, advanced therapies including high-dose insulin infusion, lipid emulsion, and glucagon may be considered [1]. The severity of this patient’s presentation progressing to syncope, circulatory shock, respiratory failure, altered mental status, and ultimately requiring transvenous pacing and CRRT illustrates the most severe end of the BRASH syndrome spectrum. Although milder cases may present with isolated or asymptomatic bradycardia, failure to promptly recognize and interrupt the vicious cycle of bradycardia, renal failure, accumulation of AV nodal blockers, shock, and hyperkalemia can rapidly lead to hemodynamic collapse and multiorgan failure [1,4]. This patient's pre-existing comorbidities significantly amplified the severity of the BRASH presentation. Pre-existing CKD reduces the margin for potassium homeostasis and drug clearance, while heart failure limits the cardiac reserve available to compensate for bradycardia-induced reductions in cardiac output [1,5]. The coexistence of these conditions in an elderly patient receiving multiple medications represents the classic high-risk substrate for BRASH syndrome. The syndrome occurs most commonly in older adults, in whom polypharmacy, CKD, and underlying cardiovascular comorbidities intersect to create marked susceptibility to the self-perpetuating cycle of bradycardia, renal failure, AV nodal blocker accumulation, shock, and hyperkalemia [5]. The initiation of CRRT in this patient served a dual purpose: correction of the hyperkalemia and metabolic acidosis driving the BRASH cycle, and management of volume overload with pulmonary edema. CRRT is the preferred modality in hemodynamically unstable patients, providing more consistent metabolic control and better cardiovascular stability than IHD [6]. The resolution of electrolyte abnormalities and acid-base derangements with CRRT effectively broke the BRASH cycle, allowing discontinuation of transvenous pacing and vasopressors. This underscores the central role of metabolic correction in the definitive management of BRASH syndrome, rather than relying solely on cardiac pacing, which addresses the symptom (bradycardia) without correcting the underlying pathophysiology [1]. This case highlights several important clinical lessons regarding BRASH syndrome. First, it underscores the importance of maintaining a high index of suspicion in patients presenting with the triad of bradycardia, renal dysfunction, and hyperkalemia while receiving AV nodal blocking agents, as BRASH syndrome remains frequently underrecognized despite its potential for rapid clinical deterioration [1,2,4]. Second, it demonstrates that effective management of BRASH syndrome requires simultaneous treatment of hyperkalemia, AV nodal blockade, renal failure, and shock rather than addressing each process in isolation [1]. Third, it highlights that patients with pre-existing CKD and heart failure are particularly vulnerable to severe BRASH syndrome due to limited renal and cardiac reserve. Finally, it underscores the important role of CRRT in hemodynamically unstable patients by successfully correcting metabolic abnormalities and helping break the BRASH cycle [1]. Conclusions BRASH syndrome is an underrecognized but potentially life-threatening clinical entity that should be considered in any patient presenting with the combination of bradycardia, renal failure, AV nodal blocker use, shock, and hyperkalemia. This case demonstrates a severe presentation complicated by multiorgan failure in a patient with significant cardiac and renal comorbidities. It illustrates the importance of early recognition, multimodal management targeting all components of the vicious cycle, and the role of CRRT in achieving definitive metabolic correction. As the population ages and the prevalence of polypharmacy, CKD, and heart failure increases, awareness of BRASH syndrome among emergency medicine, critical care, and internal medicine providers is essential to improve patient outcomes.